View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Eur Acad Dermatol Venereol 2025;39:1631–42 https:// doi. org/ 10. 1111/ jdv. 20828
This study by Lluch-Galcerá et al. provides valuable RWE to inform personalized clinical decision-making in the treatment of PsO. Authors evaluated the incidence of MACE associated with each systemic treatment used for patients with PsO and compared these rates to those observed with MTX.
Ann Rheum Dis 2025;0:1−12 Doi: 10.1016/j.ard.2025.08.006
Mease et al. showed that guselkumab provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus PBO, with no new safety signals, at Week 24 in biologic-naïve participants with active and erosive PsA. Mease et al. report primary efficacy and safety results for the double-blind PBO-controlled phase (Weeks 0-24) of the 3-year APEX study.
Gastroenterology 2025;169:308–25 Doi: 10.1053/j.gastro.2025.02.033
Results from the Phase 3 GRAVTI study by Hart et al. showed that SC induction followed by SC maintenance treatment with guselkumab resulted in superior clinical and endoscopic improvements in participants with moderately to severely active CD through 48 weeks compared with placebo. Hart et al. evaluated efficacy and safety of guselkumab SC induction followed by SC maintenance in participants with moderately to severely active CD in a treat-through design.
International Journal of Dermatology 2025;64:1401–1408 Doi: 10.1111/ijd.17814
This study by Sobotkova et al. confirmed the similar efficacy and overall safety of biological treatment for psoriasis in older and younger adult patients. Authors compared a large cohort of older adults during the first year of biological treatment for psoriasis to younger adult patients with similar characteristics to advance knowledge about the biologic treatment of psoriasis in older patients.
Clin Exp Dermatol 2025;50:1786–1794 Doi: 10.1093/ced/llaf172
This study by Mortato et al. enhanced the limited safety data on guselkumab in patients with moderate-to-severe plaque psoriasis who have clinically relevant infectious and oncological comorbidities as well as concomitant heart disease. Authors assessed clinical outcomes and safety of guselkumab in a large cohort of patients with concomitant chronic infection, cancer or heart disease over a long follow-up period, addressing critical gaps in clinical evidence.
RMD Open 2025;11:e005806 doi: 10.1136/rmdopen-2025-005806
In this nationwide observational study, ixekuzumab was mainly used in patients with axSpA and PsA who had previously failed multiple b/tsDMARDs, including other IL-17 inhibitors. Although prior IL-17 treatment was associated with increased risk of withdrawal in both groups, the relatively high retention rates and improvements in all disease outcomes suggest ixekizumab as a viable option for challenging patients with multiple b/tsDMARD failures.
Biomedicines 2025;13:2089 Doi: 10.3390/biomedicines13092089
This study by Lee et al. is the first to evaluate the association between adalimumab dosing intervals and uveitis recurrence in patients with AS. Authors investigated whether extending the dosing interval of adalimumab influences the recurrence of uveitis in AS patients with a history of AU who are on adalimumab therapy.
Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559
In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.
J Am Acad Dermatol 2025;93:104–14 doi: 10.1016/j.jaad.2025.03.016
In this nationwide study of Swedish PsO and PsA patients treated with ustekinumab, etanercept, adalimumab, or secukinumab, spanning more than 10 years, the overall risk of MACE was low across treatment groups. There was no meaningful difference in risk of MACE between ustekinumab and the other treatments.
Clinical Gastroenterology and Hepatology 2025;23:1387–1397 doi: 10.1016/j.cgh.2024.11.013
Danese et al. observed that efmarodocokin alfa did not demonstrate efficacy compared to the PBO, and this Phase II study ended early for futility; however, there was evidence of target engagement (skin AEs, regenerating islet derived protein 3-alpha).
